Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.63 |
| ▸ | DRD2 | P14416 | 4/20 | 0.63 |
| ▸ | DRD4 | P21917 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.63 |
| ▸ | ALPL | P05186 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.63 |
| ▸ | KDM1A | O60341 | 1/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20877563 | 0.84 | ADRB2 (0.71) | ADRB2ADRB1ADRB3TBXA2RDRD2 | |
| Hydrochloric Acid SCHEMBL11071599 | 0.83 | ADRB2 (0.97) | ADRB2ADRB1ADRB3TBXA2RDRD2 | |
| SCHEMBL28383642 | 0.80 | ADRB2 (0.68) | ADRB2ADRB1ADRB3TBXA2RDRD2 | |
| Hydrochloric Acid SCHEMBL11069292 | 0.80 | ADRB2 (0.74) | ADRB2ADRB1ADRB3TBXA2RDRD2 | |
| SCHEMBL29253194 | 0.79 | ADRB2 (0.63) | ADRB2ADRB1ADRB3TBXA2RDRD2 | |
| SCHEMBL221137 | 0.78 | DRD2 (1.00) | ADRB2ADRB1TBXA2RDRD2DRD4 | |
| SCHEMBL5899131 | 0.78 | ADRB2 (1.00) | ADRB2ADRB1ADRB3TBXA2RDRD2 | |
| Higenamine SCHEMBL636788 | 0.78 | DRD2 (1.00) | ADRB2ADRB1TBXA2RDRD2DRD4 | |
| (-)-Higenamine SCHEMBL5898911 | 0.78 | DRD2 (1.00) | ADRB2ADRB1TBXA2RDRD2DRD4 | |
| (+)-Higenamine SCHEMBL5898913 | 0.78 | DRD2 (1.00) | ADRB2ADRB1TBXA2RDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-7842729-B2 | Anti tubercular drug: compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-30 | — | — | US | disclosed |
| CN-101636376-A | Antituberculous drugs: compositions and methods | SEQUELLA INC | 2010-01-27 | — | — | CN | disclosed |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7456222-B2 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6951961-B2 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2005-10-04 | — | — | US | disclosed |
| US-20040033986-A1 | Anti tubercular drug: compositions and methods | PROTOPOPOVA MARINA NIKOLAEVNA (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040019117-A1 | Anti tubercular drug: compostions and methods | PROTOPOPOVA MARINA NIKOLAEVNA (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030236225-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | ADRB2 3830/4885ADRB1 3494/4885ADRB3 2948/4885 |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | RIF1, TERT, ELL | ADRB2 3184/4885ADRB1 2775/4885ADRB3 2702/4885 |
| US-20030236225-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | TERT, C5, DERA | ADRB2 3919/4885ADRB1 3543/4885ADRB3 2830/4885 |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | ADRB2 3108/4885ADRB1 2544/4885ADRB3 2215/4885 |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | ADRB2 3108/4885ADRB1 2544/4885ADRB3 2215/4885 |
| US-20040033986-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | ADRB2 3108/4885ADRB1 2544/4885ADRB3 2215/4885 |
| US-20040019117-A1 | Anti tubercular drug: compostions and methods | TYMS, TERT, TYMP | ADRB2 4113/4885ADRB1 3712/4885ADRB3 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.